Opioid Prescribing Report Cards for Opioids

Phase-Based Progress Estimates
University of Pennsylvania, Philadelphia, PA
Opioids+4 More
Opioid Prescribing Report Cards - Other
Any Age
All Sexes
What conditions do you have?

Study Summary

The objective of this research study is to evaluate the effect of a quality improvement initiative carried out by a health system opioid stewardship task force aiming to increase clinician post-operative prescribing adherence with procedure specific guidelines that were developed using patient reported data. The feedback compares the clinician's average number of opioid pills prescribed after a given procedure to other clinicians in the health system and to the health system guideline recommended amount based on patient reported data on opioid pills taken for that procedure. The feedback also provides historical data on mean patient reported number opioid pills taken following a given procedure and on patients' ability to manage pain among those who received guideline adherent prescriptions compared with patients who received greater than the guideline recommended amount.

Eligible Conditions

  • Opioids
  • Opioids Use
  • Surgery

Treatment Effectiveness

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: The duration of the study; two years

28 days
Perceived ability to manage pain
Pills Taken
30 days
Health care utilization - Emergency Department Visits
Health care utilization - Hospitalizations
Health care utilization - Office Visits
Health care utilization - Telephone Calls
Number of Prescription Refills
The duration of the study; two years
Pills Prescribed
ten months
Guideline Adherent Opioid Prescriptions

Trial Safety

Trial Design

2 Treatment Groups

Standard Feedback
1 of 2
Opioid Prescribing Report Cards
1 of 2
Active Control
Experimental Treatment

550 Total Participants · 2 Treatment Groups

Primary Treatment: Opioid Prescribing Report Cards · No Placebo Group · N/A

Opioid Prescribing Report Cards
Experimental Group · 1 Intervention: Opioid Prescribing Report Cards · Intervention Types: Other
Standard FeedbackNoIntervention Group · 1 Intervention: Standard Feedback · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: the duration of the study; two years
Closest Location: University of Pennsylvania · Philadelphia, PA
Photo of Hospital of the University of Pennsylvania 1Photo of Hospital of the University of Pennsylvania 2Photo of University of Pennsylvania 3
2011First Recorded Clinical Trial
1 TrialsResearching Opioids
1053 CompletedClinical Trials

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,797 Previous Clinical Trials
36,106,012 Total Patients Enrolled
1 Trials studying Opioids
108 Patients Enrolled for Opioids
Dan Lee, MDPrincipal InvestigatorUniversity of Pennsylvania
Zarina Ali, MDPrincipal InvestigatorUniversity of Pennsylvania
2 Previous Clinical Trials
857 Total Patients Enrolled
M. Kit Delgado, MD, MSPrincipal InvestigatorUniversity of Pennsylvania
3 Previous Clinical Trials
2,328 Total Patients Enrolled
Anish Agarwal, MD, MPHPrincipal InvestigatorUniversity of Pennsylvania

Eligibility Criteria

Age Any Age · All Participants · 3 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a surgeon or an advanced practice provider who has written at least 5 opioid prescriptions per month for patients undergoing an eligible procedure during the baseline period or an attending surgeon who performed an eligible procedure during the baseline period.
Patients will be included in the primary sample if they (1) undergo an eligible surgical procedure by an eligible attending surgeon, and (2) the proportion of guideline compliant prescriptions written during the baseline period for that procedure was less than 90%.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.